YU47934B - Novi derivati ksantina sa antagonističnim dejstvom prema adenziju - Google Patents

Novi derivati ksantina sa antagonističnim dejstvom prema adenziju

Info

Publication number
YU47934B
YU47934B YU242389A YU242389A YU47934B YU 47934 B YU47934 B YU 47934B YU 242389 A YU242389 A YU 242389A YU 242389 A YU242389 A YU 242389A YU 47934 B YU47934 B YU 47934B
Authority
YU
Yugoslavia
Prior art keywords
substd
opt
alkyl
cycloalkyl
alkenyl
Prior art date
Application number
YU242389A
Other languages
English (en)
Other versions
YU242389A (en
Inventor
K.U. Muhl
H.K. Weber
G. Walther
W. Stransky
H. Ensinger
G. Schingnitz
J.F. Kuhn
E. Lehr
Original Assignee
Boehringer Ingelheim Kg.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Kg. filed Critical Boehringer Ingelheim Kg.
Priority to SI8912423A priority Critical patent/SI8912423B/sl
Publication of YU242389A publication Critical patent/YU242389A/xx
Priority to HRP-2423/89A priority patent/HRP940724A2/hr
Publication of YU47934B publication Critical patent/YU47934B/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

NOVI DERIVATI KSANTINA SA ANTAGONISTIČNIM DEJSTVOM PREMA ADENZIJU, novi ksantini opšte formule I u kojoj R1 označava alkil-grupu, sa 1 do 4, atoma ugljenika; R2 označava alkil-grupu, sa 1 do 4, atoma ugljenika; R3 označava furan, supstituisan sa CONR5R6; R3 označava tetrahidropiran-4-il ili ditiolan; R3 označava C5-cikloalkanon ili C5-cikloalkanol; R3 označava C5-cikloalkan, koji je supstituisan sa C1 do C6, prvenstveno C1 do C4-alkil, =CH2, OR4, OR7, -CH2-OH, -OCONH-fenil ili =N-NH-fenil-grupom, pri čemu fenil-ostatak može da bude supstituisan, ili sa ostatkom =CAH, pri čemu A može da predstavlja COOR4; ili cikloalkan, supstituisan metil-grupom, a kao drugi supstituent sadrži hidroksil-grupu u geminalnom položaju u odnosu na prvi supstituent; R3 označava ostatak formule R4 označava vodonik, alkil-grupu sa 1 do 6 atoma ugljenika; R5 označava vodonik, alkil-grupu sa 1 do 4 atoma ugljenika; R6 označava vodonik, alkil-grupu sa 1 do 6 atoma ugljenika, eventualno supstituisanu benzil-grupu, ostatak opšte formule -(CH2)n-NR5R5 (R5 isti ili različiti), sa n=2, piperidinil-ostatak vezan preko ugljenika, koji je eventualno supstituisan sa C1 do C4-alikl-grupom ili sa benzil-ostatkom vezanim preko azota; R7 označava CO-C1-C13-alkil, prvenstveno CO-C2-C4-alkil, eventual-no supstituisan benzoil-ostatak, prevenstveno trimetoksibenzoil, os-tatak opšte formule CO-piridinil, eventualno kao i njihove racemate, njihova optički aktivna jedinjenja kao i njihove adicione soli sa kiselinama. Prijava sadrži još 4 nezavis-na i 1 zavisan zahtev.
YU242389A 1988-12-22 1989-12-20 Novi derivati ksantina sa antagonističnim dejstvom prema adenziju YU47934B (sh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SI8912423A SI8912423B (sl) 1988-12-22 1989-12-20 Novi derivati ksantina z antagonističnim učinkom proti adenozinu
HRP-2423/89A HRP940724A2 (en) 1988-12-22 1994-10-21 Novel xantin derivatives having an adenosin-antagonistic activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3843117A DE3843117A1 (de) 1988-12-22 1988-12-22 Neue xanthinderivate mit adenosin-antagonistischer wirkung

Publications (2)

Publication Number Publication Date
YU242389A YU242389A (en) 1991-10-31
YU47934B true YU47934B (sh) 1996-05-20

Family

ID=6369764

Family Applications (1)

Application Number Title Priority Date Filing Date
YU242389A YU47934B (sh) 1988-12-22 1989-12-20 Novi derivati ksantina sa antagonističnim dejstvom prema adenziju

Country Status (32)

Country Link
US (4) US5175291A (sh)
EP (1) EP0374808B1 (sh)
JP (1) JP2565576B2 (sh)
KR (1) KR0165666B1 (sh)
AT (1) ATE136897T1 (sh)
BG (1) BG61669B2 (sh)
BR (1) BR1100527A (sh)
CA (1) CA2006387C (sh)
CZ (1) CZ286230B6 (sh)
DD (1) DD290421A5 (sh)
DE (3) DE3843117A1 (sh)
DK (1) DK652689A (sh)
ES (1) ES2086313T3 (sh)
FI (1) FI96513C (sh)
GR (1) GR3019733T3 (sh)
HR (1) HRP940724A2 (sh)
HU (1) HU218674B (sh)
IE (1) IE74205B1 (sh)
IL (1) IL92829A (sh)
MX (1) MX9203618A (sh)
NO (1) NO173502C (sh)
NZ (1) NZ231901A (sh)
PH (2) PH31107A (sh)
PL (1) PL162877B1 (sh)
PT (1) PT92658B (sh)
RU (1) RU2057752C1 (sh)
SG (1) SG46380A1 (sh)
SI (1) SI8912423B (sh)
SK (1) SK719789A3 (sh)
UA (1) UA26427A (sh)
YU (1) YU47934B (sh)
ZA (1) ZA899881B (sh)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
US5290782A (en) * 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
US5047534A (en) * 1990-03-26 1991-09-10 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
CA2061544A1 (en) * 1991-02-25 1992-08-26 Fumio Suzuki Xanthine compounds
GB9111130D0 (en) * 1991-05-23 1991-07-17 Ici Plc Azole derivatives
GB9111131D0 (en) * 1991-05-23 1991-07-17 Ici Plc Heterocyclic compounds
CA2082325A1 (en) * 1991-11-08 1993-05-09 Fumio Suzuki Xanthine derivatives
IT1260444B (it) * 1992-01-24 1996-04-09 Mario Brufani Derivati della 8-(1-amminocicloalchil)1,3-dialchilxantina, procedimenbto di preparazione e loro composizioni farmaceutiche antidepressive, nootropiche e psicostimolanti
US5336769A (en) * 1992-02-17 1994-08-09 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
US5484920A (en) * 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
CA2093403C (en) * 1992-04-08 1999-08-10 Fumio Suzuki Therapeutic agent for parkinson's disease
WO1994003173A1 (de) * 1992-08-01 1994-02-17 Boehringer Ingelheim Kg Verwendung von 8-(3-oxocyclopentyl)-1,3-dipropyl-7h-purin-2,6-dion zur symptomatischen behandlung der zystischen fibrose
TW252044B (sh) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
US5288721A (en) * 1992-09-22 1994-02-22 Cell Therapeutics, Inc. Substituted epoxyalkyl xanthines
JP2613355B2 (ja) * 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
US5877179A (en) * 1992-09-29 1999-03-02 The United States Of America As Represented By The Department Of Health And Human Services Xanthines for identifying CFTR--binding compounds useful for activating chloride conductance in animal cells
DE4236331A1 (de) * 1992-10-28 1994-05-05 Boehringer Ingelheim Kg Synergistische Kombination
WO1994015605A1 (en) * 1993-01-14 1994-07-21 Cell Therapeutics, Inc. Acetal or ketal substituted therapeutic compounds
HUT72677A (en) * 1993-02-26 1996-05-28 Merrell Dow Pharma Xanthine derivatives as adenosine a1 receptor antagonists
WO1994025462A1 (en) * 1993-05-03 1994-11-10 The United States Of America, Represented By The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
DE4316576A1 (de) * 1993-05-18 1994-11-24 Boehringer Ingelheim Kg Verbessertes Verfahren zur Herstellung von 1,3-Dipropyl-8-(3-Oxocyclopentyl)-xanthin
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
US5736528A (en) * 1993-10-28 1998-04-07 University Of Florida Research Foundation, Inc. N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
JP3769737B2 (ja) * 1994-03-30 2006-04-26 味の素株式会社 シクロプロパン誘導体及びその製造法
US5591776A (en) * 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
EP0799040B1 (en) * 1994-12-13 2003-08-20 Euroceltique S.A. Trisubstituted thioxanthines
ATE247116T1 (de) * 1994-12-13 2003-08-15 Euro Celtique Sa Arylthioxanthine
US5864037A (en) 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
US5786360A (en) 1996-11-19 1998-07-28 Link Technology Incorporated A1 adenosine receptor antagonists
US6727259B2 (en) * 1997-09-05 2004-04-27 Kyowa Hakko Kogyo Co., Ltd. Remedial agent for neural degeneration
US6248746B1 (en) 1998-01-07 2001-06-19 Euro-Celtique S.A. 3-(arylalkyl) xanthines
DE19816857A1 (de) * 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6521656B1 (en) * 1998-06-01 2003-02-18 Fujisawa Pharmaceutical Co., Ltd. Remedies for male sterility
WO2000002861A1 (en) 1998-07-10 2000-01-20 The United States Of America, Represented By Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists
US6025362A (en) * 1998-08-31 2000-02-15 Fukunaga; Atsuo F. Uses of xanthine compounds
US6576619B2 (en) 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
US6545002B1 (en) * 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
EP2070930A1 (en) * 1999-11-12 2009-06-17 Biogen Idec MA, Inc. Polycycloalkylpurines as adenosine receptor antagonists
EP1775297A3 (en) * 1999-11-12 2008-12-03 Biogen Idec MA Inc. Adenosine receptor antagonists and methods of making and using the same
AU2001230913B2 (en) 2000-01-14 2005-06-30 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methanocarba cycloalkyl nucleoside analogues
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
EP1444233B1 (en) 2001-11-09 2011-08-17 Gilead Palo Alto, Inc. A2b adenosine receptor antagonists
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
WO2004009594A2 (en) * 2002-07-19 2004-01-29 Aryx Therapeutics Xanthine derivatives having adenosine a1-receptor antagonist properties
US7202252B2 (en) 2003-02-19 2007-04-10 Endacea, Inc. A1 adenosine receptor antagonists
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
US20060293312A1 (en) * 2003-04-25 2006-12-28 Howard Dittrich Method of improved diuresis in individuals with impaired renal function
CA2522971A1 (en) * 2003-04-25 2004-11-11 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
WO2004106337A1 (en) * 2003-05-06 2004-12-09 Cv Therapeutics, Inc. Xanthine derivatives as a2b adenosine receptor antagonists
CA2528385C (en) * 2003-06-06 2011-03-15 Endacea, Inc. A1 adenosine receptor antogonists
EP1636230A4 (en) * 2003-06-09 2010-06-16 Endacea Inc ADENOSINE A1 RECEPTOR ANTAGONISTS
TW200507882A (en) * 2003-07-17 2005-03-01 Kyowa Hakko Kogyo Kk Solid formulations
US6847249B1 (en) * 2003-10-09 2005-01-25 Analog Devices, Inc. Highest available voltage selector circuit
KR20070008689A (ko) * 2004-04-16 2007-01-17 노바카르디아, 인코포레이션 아데노신 ａ１ 수용체 길항제 및 알도스테론 억제제를포함하는 병용 요법
JP4929173B2 (ja) * 2004-09-01 2012-05-09 ギリアード・パロ・アルト・インコーポレイテッド Ａ２ｂアデノシンレセプターアンタゴニストを使用する創傷治癒の方法
CN101466383A (zh) * 2006-06-16 2009-06-24 美国诺华卡迪亚公司 包含低频率投与aa1ra的肾功能延长改善
US8193200B2 (en) 2007-01-04 2012-06-05 University Of Virginia Patent Foundation Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
US20090197900A1 (en) * 2007-03-29 2009-08-06 Howard Dittrich Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
JP5460690B2 (ja) * 2008-03-26 2014-04-02 アドヴィナス・セラピューティックス・リミテッド アデノシンレセプターアンタゴニストとしてのヘテロ環化合物
US8129862B2 (en) * 2009-10-23 2012-03-06 Analog Devices, Inc. Scalable highest available voltage selector circuit
WO2011055391A1 (en) * 2009-11-09 2011-05-12 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds, its preparation and uses thereof
US8518957B2 (en) 2009-12-02 2013-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methanocarba adenosine derivatives, pharmaceutical compositions, and method of reducing intraocular pressure

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1201997A (en) * 1967-08-04 1970-08-12 Yissum Res Dev Co New substituted purines and purine derivatives
US3624216A (en) * 1970-06-25 1971-11-30 Abbott Lab 8-substituted theophyllines as anti-inflammatory agents
US3624215A (en) * 1970-06-25 1971-11-30 Abbott Lab 8-substituted theophyllines as anti-anxiety agents
DE3028273A1 (de) * 1980-07-25 1982-02-25 Fa. Dr. Willmar Schwabe, 7500 Karlsruhe Durch purinbasen substituierte 1.4;3.6-dianhydro-hexit-nitrate
ES517622A0 (es) * 1982-11-23 1983-12-16 Faes Procedimiento de preparacion de un nuevo espirodecano.
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4548939A (en) * 1984-10-01 1985-10-22 Janssen Pharmaceutica N. V. 1H-Indol-3-yl containing 1,3-dimethyl-1H-purine-2,6-diones
US4755517A (en) * 1986-07-31 1988-07-05 Warner-Lambert Company Derivatives of xanthine, pharmaceutical compositions and methods of use therefor
US5175290A (en) * 1988-09-16 1992-12-29 Marion Merrell Dow Inc. 8-(oxo-substituted cycloalkyl)xanthines
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
US5290782A (en) * 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
US4957921A (en) * 1989-12-06 1990-09-18 Warner-Lambert Company Substituted cyclohexanols as central nervous system agents
CA2082325A1 (en) * 1991-11-08 1993-05-09 Fumio Suzuki Xanthine derivatives

Also Published As

Publication number Publication date
DE8817122U1 (de) 1993-02-04
DE58909657D1 (de) 1996-05-23
FI896117A0 (fi) 1989-12-20
US5532368A (en) 1996-07-02
PL162877B1 (pl) 1994-01-31
CZ286230B6 (cs) 2000-02-16
GR3019733T3 (en) 1996-07-31
IL92829A0 (en) 1990-09-17
EP0374808B1 (de) 1996-04-17
HUT52503A (en) 1990-07-28
PL282878A1 (en) 1992-03-09
DK652689A (da) 1990-06-23
NO173502B (no) 1993-09-13
YU242389A (en) 1991-10-31
IL92829A (en) 1995-12-31
FI96513B (fi) 1996-03-29
DE3843117A1 (de) 1990-06-28
RU2057752C1 (ru) 1996-04-10
US5696124A (en) 1997-12-09
HU896736D0 (en) 1990-02-28
ATE136897T1 (de) 1996-05-15
PT92658A (pt) 1990-06-29
DK652689D0 (da) 1989-12-21
SK279525B6 (sk) 1998-12-02
KR900009646A (ko) 1990-07-05
SG46380A1 (en) 1998-02-20
SI8912423B (sl) 1998-12-31
KR0165666B1 (ko) 1999-01-15
PH31111A (en) 1998-02-23
NZ231901A (en) 1993-12-23
MX9203618A (es) 1992-09-01
FI96513C (fi) 1996-07-10
CA2006387A1 (en) 1990-06-22
US5175291A (en) 1992-12-29
ZA899881B (en) 1991-08-28
US5688802A (en) 1997-11-18
IE894147L (en) 1990-06-22
NO895168L (no) 1990-06-25
CA2006387C (en) 2000-02-08
SI8912423A (sl) 1998-04-30
UA26427A (uk) 1999-08-30
CZ719789A3 (cs) 1999-10-13
NO173502C (no) 1993-12-22
JPH02247180A (ja) 1990-10-02
PH31107A (en) 1998-02-23
JP2565576B2 (ja) 1996-12-18
PT92658B (pt) 1995-09-12
HU218674B (hu) 2000-10-28
IE74205B1 (en) 1997-07-16
SK719789A3 (en) 1998-12-02
BR1100527A (pt) 2000-08-01
HRP940724A2 (en) 1997-06-30
EP0374808A2 (de) 1990-06-27
ES2086313T3 (es) 1996-07-01
DD290421A5 (de) 1991-05-29
AU4707289A (en) 1990-06-28
AU637990B2 (en) 1993-06-17
BG61669B2 (bg) 1998-02-27
EP0374808A3 (de) 1991-05-15
NO895168D0 (no) 1989-12-21

Similar Documents

Publication Publication Date Title
YU47934B (sh) Novi derivati ksantina sa antagonističnim dejstvom prema adenziju
DK148279C (da) Analogifremgangsmaade til fremstilling af 9-substituerede guaninderivater eller fysiologisk acceptable salte eller optiske isomerer deraf
DK653088A (da) Anti-inflammatoriske derivater af di-tert-butylphenolforbindelser og farmaceutisk middel omfattende samme
KR850003533A (ko) 1,3-디옥산 유도체의 제조방법
FR2671349B1 (fr) Nouveaux derives de 1,4-dihydropyridine, leur procede de preparation et composition therapeutique les contenant.
KR860002508A (ko) 푸로(3,2-c)피리딘 유도체, 그의 제법 및 그를 포함하는 의약 조성물
ES2128332T3 (es) Metodo para la produccion de la 2-amino-6-halogenopurina y sintesis de un intermediario.
US4102900A (en) 3-(1'-Silyloxy-3'-hydroxyethyl)-4-hydroxy-6-silyloxyhexanoic acid γ la
Corey et al. Tricyclo [23, 6.1. 1.0] pyran-2-one
Troyansky et al. Remote asymmetric induction in free radical cycloaddition leading to trans-cyclohexano-fused 12-membered crown thioethers
KR830007592A (ko) 약리활성체 4-[2-히드록시-4-(치환)페닐]나프탈렌-2(1h)-온 및 2-올, 이들 유도체 및 이들 중간체의 제조방법
ATE110079T1 (de) Triazolo(1,5-c>pyrimido(1,4>azine als bronchodilatatoren.
FR2579813B1 (fr) Procede de synthese sonore par composition d'interceptions de rayons lumineux